In July 2025, new data highlighted the profound impact of tariffs imposed during the Trump era, showing a clear correlation with rising inflation concerns, leading to a noticeable dip in the stock market. The latest figures from June reveal how these tariffs have increased production costs, causing price hikes across various sectors. Investors worry about the Federal Reserve’s next moves, as Chairman Powell continues to emphasize a vigilant approach to curbing inflation. These concerns have stirred apprehensions among market participants, prompting a shift towards safer assets and away from equities. The ripple effects of the Trump tariffs are being felt globally, with analysts predicting further economic adjustment periods. As inflation remains a key issue, the stock market’s volatility may persist, testing resilience amid escalating price pressures.
FortuneNew data shows CLYM116 reduces key IgA nephropathy biomarkers by ~70%, supporting a 12-week dosing regimen
October 24, 2026
New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%.